Advertisement
"Genaera is privileged and honored to work with this prestigious group ofnationally and internationally recognized experts to guide our MSI-1436clinical development," commented Jack Armstrong, President and CEO of Genaera."The expertise of this advisory board is a valuable resource to help ensureGenaera adopts the most scientifically focused and clinically effectivedevelopment plan as we move forward with this unique therapeutic agent."
Advertisement
"With more than 60 million Americans classified as obese, there is acritical need for innovative therapies to manage metabolic disorders," notedDr. Thomas Wadden, Professor of Psychology and Director of the Center forWeight Loss and Eating Disorders at the University of Pennsylvania. "I ampleased to serve on Genaera's SAB to provide direction on the current andfuture development of this therapeutic agent for the treatment of both obesityand type 2 diabetes."
"Despite recent advances, obesity and diabetes remain major global healthissues," stated Dr. Louis Aronne, Clinical Professor of Medicine at the WeillCornell Medical College. "Targeting these areas for future clinical researchwill have a major public health impact. Although early in development,trodusquemine is among the promising therapies in development for thetreatment of these challenging disorders."
Today, the SAB met to review updated preclinical and new Phase I data onMSI-1436 and provided guidance on the design and conduct of future clinicalstudies to assure that appropriate safety assessments are addressed and thatthe trials can maximize detection of the biochemical and/or clinical signalsthat predict clinical utility. Additionally, the SAB will address importantissues related to the development of a commercially viable agent for thetreatment of both obesity and diabetes including emerging changes in theglobal medical and regulatory environment.
Genaera's Scientific Advisory Board
Louis J. Aronne, M.D., FACP is Clinical Professor of Medicine at the WeillCornell Medical College and the Director of the Comprehensive Weight ControlProgram, a state-of-the-art multidisciplinary obesity research and treatmentprogram. Dr. Aronne is also Adjunct Associate Professor of Medicine atColumbia University College of Physicians and Surgeons, and AttendingPhysician at the New York Presbyterian Hospital.
Mitchell A. Lazar, M.D., Ph.D. is the Sylvan Eisman Professor of Medicineat the University of Pennsylvania School of Medicine, where he is alsoDirector of the Institute for Diabetes, Obesity, and Metabolism and Chief ofthe Division of Endocrinology, Diabetes, and Metabolism. Dr. Lazar has beenelected to the American Society for Clinical Investigation, the Association ofAmerican Physicians, and the Institute of Medicine of the National Academy ofSciences.
F. Xavier Pi-Sunyer, M.D., Ph.D. is Professor of Medicine at ColumbiaUniversity College of Physicians and Surgeons. At St. Luke's-RooseveltHospital Center he serves as Chief of Endocrinology, Diabetes, and Nutrition,and is Director of the New York Obesity Research Center. Dr. Pi-Sunyer is alsoa Senior Attending Physician at St. Luke's-Roosevelt Hospital andNew York-Presbyterian Hospital. He recently chaired the committee of theNational Heart, Lung, and Blood Institute that researched and defined thefederal government's new guidelines for the prevention and treatment ofobesity. He has served as president of the American Diabetes Association, theAmerican Society for Clinica
